Please assess the completion status of the following clinical trial:

Trial Title: Clinical Studies on Bile Acids in Barrett's Esophagus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have been scheduled for elective endoscopic examination at the Dallas VA Medical Center for the evaluation of GERD or Barrett's esophagus~Exclusion Criteria:~* Patients unwilling or unable to provide informed consent~* Patients with esophageal carcinomas~* Patients with esophageal varices~* Patients taking warfarin or clopidogrel~* Coagulopathy that precludes safe biopsy of the esophagus~* Comorbidity that precludes safe participation in the study~* Allergy to omeprazole or UDCA~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): All patients are treated with DCA and UDCA perfusion of the esophagus, one year apart, followed by 8 weeks of treatment with oral ursodeoxycholic acid 10 mg/kg qd. Then a final DCA perfusion of the esophagus.

Based on this trial design, predict the completion outcome and termination type (if applicable).